|
|
|
|
|
|
|
|
|
|
Oct. 9 /PRNewswire/ -- Amgen today announced AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The updated results, now including data on overall survival, are being presented in a poster discussion at the 35th European Society for Medical Oncology (ESMO) Congress being held in Milan, Italy. (Abstract Number: 975PD)...."cont'd
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.